BTIG analyst Thomas Catherwood downgrades Boston Properties (NYSE:BXP) from Buy to Neutral.
Praxis Precision Medicines Priced $200M Offering of 3.3M Shares at $56.50/Share
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by